Benzathine analogs
US-2019091222-A1 · Mar 28, 2019 · US
Benzathine analogs
US10869866B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10869866-B2 |
| Application number | US-201916444879-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2019 |
| Priority date | Jun 8, 2012 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of formula II: wherein X is an optionally-substituted aryldiyl; and R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocycle, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an N-heterocycle selected from pyrrolyl, H-pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, oxadiazolyl, isoxazolyl, furazanyl, thiazolyl, isothiazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or triazinyl. 2. The compound of claim 1 , wherein R 3 is an N-heterocycle and R 8 is an N-heterocycle. 3. The compound of claim 1 , wherein the N-heterocycle is selected from imidazolyl, pyridyl, pyrazolyl, oxadiazolyl, or pyrimidinyl. 4. The compound of claim 1 , wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9 and R 10 are each H, and R 3 and R 8 are not H. 5. A pharmaceutical composition comprising at least one compound of claim 1 , and at least one pharmaceutically acceptable additive. 6. The compound of claim 1 , wherein X is phenylenediyl. 7. The compound of claim 1 , wherein the N-heterocycle is pyrazolidinyl. 8. The compound of claim 1 , wherein R 3 and R 8 are each pyrazolidinyl. 9. The compound of claim 6 , wherein R 3 and R 8 are each pyrazolidinyl. 10. The compound of claim 1 , wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9 and R 10 are each H, and R 3 and R 8 are each pyrazolidinyl. 11. The compound of claim 2 , wherein X is phenylenediyl. 12. The compound of claim 10 , wherein X is phenylenediyl.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
having five-membered rings · CPC title
having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10869866B2 cover?
- A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted ar…
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, Us Gov Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).